Mantle cell lymphoma presented as multiple lymphomatous polyposis: clinical review of 4 cases.
- Author:
Dong Hwan KIM
1
;
Sang Kyun SOHN
;
Jin Tae JUNG
;
Ki Youn KIM
;
Dong Seok KWAK
;
Tae In PARK
;
So Hyang PARK
;
Han Ik BAE
;
Jang Soo SUH
;
Kyu Bo LEE
Author Information
1. Department of Internal Medicine, Kyungpook National University, School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Lymphoma;
Mantlee - cell;
Multiple lymphomatous polyposis
- MeSH:
Drug Therapy;
Gastrointestinal Tract;
Humans;
Lymphatic Diseases;
Lymphoma;
Lymphoma, B-Cell;
Lymphoma, Mantle-Cell*;
Polyps;
Splenomegaly;
Stem Cells
- From:Korean Journal of Medicine
2000;59(4):413-422
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Multiple lymphomatous polyposis(MLP) is an interesting clinical entity of non-Hodgkin's lymphoma(NHL) and is defined as B-cell lymphoma characterized by the presence of multiple lymphomatous polyps along the gastrointestinal tract. Recently MLP has been considered as a variant form of mantle cell lymphoma(MCL). The median survival of patients with MCL is only 3 years, and none of the available conventional chemotherapy regimens appears curative. Encouraging results have been reported with high dose chemotherapy with autoSCT and alloSCT for its treatment. We introduce 4 cases of MLP diagnosed as MCL by morphologic and immunologic method. The common clinical findings of these cases were splenomegaly (4/4), multiple intraabdominal lymphadenopathy (4/4), and advanced stage (3/4) at presentation. The overall remission duration was relatively short (5-27 months) and three of four cases relapsed after conventional chemotherapy or autologous stem cell transplant. Our report suggests that MCL presented as MLP is a high risk subgroup of NHL and more aggressive approach may be needed for cure.
